Key Events This Week
4 May: Week opens at Rs.518.40
5 May: Rating upgraded to Sell on technical improvements
6 May: Technical momentum shifts amid mixed signals
8 May: Week closes at Rs.525.45 (+1.36%)
May 15
BSE+NSE Vol: 41.99 lacs

The Sensex advanced 0.40% on 15 May 2026, but Solara Active Pharma Sciences Ltd outpaced the broader market with a remarkable 13.47% gain, reaching an intraday high of Rs 551.7. This 7.75 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally rather than a general market upswing.
Read full news article
Solara Active Pharma Sciences Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 11 May 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some valuation appeal, the company’s financial trends and quality metrics have raised significant concerns, prompting a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.
Read full news article
Solara Active Pharma Sciences Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest day gain of 0.32%, the company’s technical indicators present a complex picture, with weekly and monthly signals diverging across key metrics such as MACD, RSI, Bollinger Bands, and moving averages. This nuanced technical landscape warrants close attention from investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article
4 May: Week opens at Rs.518.40
5 May: Rating upgraded to Sell on technical improvements
6 May: Technical momentum shifts amid mixed signals
8 May: Week closes at Rs.525.45 (+1.36%)

Solara Active Pharma Sciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 5 May 2026, driven primarily by an improvement in technical indicators despite persistent fundamental challenges. The company’s technical trend has shifted from mildly bearish to sideways, prompting a reassessment of its outlook. However, weak financial performance and long-term profitability concerns continue to weigh on the stock’s prospects.
Read full news article
Solara Active Pharma Sciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent downgrade in its Mojo Grade to 'Sell' from 'Strong Sell', the stock exhibits a complex interplay of bullish and bearish signals across key technical indicators, reflecting a nuanced market sentiment.
Read full news article
Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025, reflecting a reassessment of the company’s outlook. However, the analysis and financial metrics discussed here represent the stock’s current position as of 25 April 2026, providing investors with the latest insights into its performance and prospects.
Read full news article
Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news articleRevised Intimation of Schedule of Investors/Analysts call to be held on Friday May 15 2026 15.00 IST to discuss the Companys audited financial results for the quarter and year ended March 31 2026
Solara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Friday May 15 2026 at 15.00 IST to discuss the Companys audited financial results for the quarter and year ended March 31 2026
Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 inter alia to consider and approve the audited standalone and consolidated financial results of the Company for the quarter and year ended March 31 2026
(15 May 2026)
Solara Active Pharma Sciences Ltd has declared 30% dividend, ex-date: 18 Aug 21
No Splits history available
No Bonus history available
Solara Active Pharma Sciences Ltd has announced 1:3 rights issue, ex-date: 15 May 24